Meropenem sodium
Based on 30 publication(s) in Google Scholar
Meropenem sodium is a carbapenem antibiotic with broad-spectrum antibacterial activity. Meropenem sodium has activity against susceptible and resistant N. gonorrhoeae (MIC value of 0.02-0.06 mg/mL), H. influenzae (MIC value of 0.03-0.12 mg/mL), and H. ducreyi (MIC value of 0.015-0.12 mg/mL).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 211238-34-5
- 分子式: C17H24N3NaO5S
- 分子量:405.44
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
MedChemExpress(MCE)の使用を引用している文献 Meropenem sodium
More- Nat Microbiol. 2023 Mar;8(3):410-423. [Abstract]
- Nat Commun. 2022 Mar 2;13(1):1116. [Abstract]
- Nano Today. 2024 Dec.
- J Exp Med. 2026 Mar 2;223(3):e20241287. [Abstract]
- Proc Natl Acad Sci U S A. 2024 Jan 16;121(3):e2314514121. [Abstract]
- Emerg Microbes Infect. 2024 Dec;13(1):2321981. [Abstract]
- Biomed Pharmacother. 2023 Dec 31:169:115856. [Abstract]
- Virulence. 2026 Dec 31;17(1):2646808. [Abstract]
- Bioorg Chem. 2025 Jun 1:159:108421. [Abstract]
- Int J Antimicrob Agents. 2025 Jun 9:107551. [Abstract]
- Spectrochim Acta A Mol Biomol Spectrosc. 2020 Apr 5;230:118066. [Abstract]
- mLife. 2025 Apr 15;4(2):155-168. [Abstract]
- FASEB J. 2026 Jan 31;40(2):e71438. [Abstract]
- BMC Microbiol. 2025 Apr 29;25(1):257. [Abstract]
- Microorganisms. 2024 Mar 13;12(3):575. [Abstract]
- Microbiol Spectr. 2025 Oct 16:e0160325. [Abstract]
- Microbiol Spectr. 2024 Aug 6;12(8):e0397923. [Abstract]
- Open Forum Infect Dis. 2023 Jan 27;10(2):ofad038. [Abstract]
- J Antimicrob Chemother. 2026 Jun 3;81(7):dkag204. [Abstract]
- J Antimicrob Chemother. 2026 Feb 2;81(3):dkag034. [Abstract]
- J Antimicrob Chemother. 2025 Nov 5:dkaf408. [Abstract]
- J Antimicrob Chemother. 2020 Jul 1;75(7):1850-1858. [Abstract]
- J Glob Antimicrob Resist. 2025 Apr 26:S2213-7165(25)00088-8. [Abstract]
- Eur J Clin Microbiol Infect Dis. 2025 Sep 29. [Abstract]
- Infect Drug Resist. 2026 May 8;19.
- Infect Drug Resist. 2021 Jun 30;14:2499-2507. [Abstract]
- J Antibiot (Tokyo). 2026 Feb 17. [Abstract]
- Infect Genet Evol. 2025 Sep:133:105780. [Abstract]
- J Microbiol Methods. 2026 Feb 25:107441. [Abstract]
- Diagn Microbiol Infect Dis. 2026 Feb;114(2):117181. [Abstract]
-
Microbiological Assay
-
Microbiological Assay
-
Microbiological Assay
-
Microbiological Assay
-
Microbiological Assay
Antibiotic アイソフォーム固有の製品をすべて表示
More
生物活性
化学情報
-
CAS 番号 211238-34-5
-
分子量 405.44
-
分子式 C17H24N3NaO5S
-
SMILES
O=C(C1=C(S[C@H]2C[C@H](NC2)C(N(C)C)=O)[C@H](C)[C@@]([C@@]3([H])[C@H](O)C)([H])N1C3=O)O[Na]
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (30)
-
Journal Impact Factor
-
Most Recent
-
Nat Microbiol
Characterization of antibiotic resistomes by reprogrammed bacteriophage-enabled functional metagenomics in clinical strains. [Abstract]2023 Mar;8(3):410-423. PMID: 36759752 -
Nat Commun
Antimicrobial resistance and population genomics of multidrug-resistant Escherichia coli in pig farms in mainland China. [Abstract]2022 Mar 2;13(1):1116. PMID: 35236849
Meropenem sodium purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Mar 2;13(1):1116. [Abstract]
Resistance rates of Escherichia coli isolates from farms in different provinces of mainland China to different classes of antibiotics, including Meropenem.
-
-
J Exp Med
2026 Mar 2;223(3):e20241287. PMID: 41400657 -
Proc Natl Acad Sci U S A
In-patient evolution of a high-persister Escherichia coli strain with reduced in vivo antibiotic susceptibility. [Abstract]2024 Jan 16;121(3):e2314514121. PMID: 38190524 -
Emerg Microbes Infect
AMXT-1501 targets membrane phospholipids against Gram-positive and -negative multidrug-resistant bacteria. [Abstract]2024 Dec;13(1):2321981. PMID: 38422452
Meropenem sodium purchased from MedChemExpress. Usage Cited in: Emerg Microbes Infect. 2024 Dec;13(1):2321981. [Abstract]
Antibacterial activity of AMXT-1501 against K. pneumoniae, an ESBL-producing E. coli, and carbapenem-resistant Enterobacteriaceae E. coli detected by time-killing assays; compared with meropenem or tigecycline (final concentration at 8× MIC); The dashed lines indicated the limit of detection of time-killing assays. Antibacterial activity of AMXT-1501 against abdominal infected with E. coli ECO2219 (n = 15/group); compared with TIG.
-
Biomed Pharmacother
The enhancement effect of small molecule Lyb24 reveals AzoR as a novel target of polymyxin B. [Abstract]2023 Dec 31:169:115856. PMID: 37949698 -
Virulence
Antibacterial efficacy and mechanism of the novel antimicrobial peptide lachnospirin-1 against Acinetobacter baumannii. [Abstract]2026 Dec 31;17(1):2646808. PMID: 41838520 -
Bioorg Chem
Repurposing tavaborole to combat resistant bacterial infections through competitive inhibition of KPC-2 and metabolic disruption. [Abstract]2025 Jun 1:159:108421. PMID: 40179579 -
Int J Antimicrob Agents
Elucidating adaptive compensatory tigecycline resistance mechanisms of RamA, RarA and SoxS in Klebsiella pneumoniae. [Abstract]2025 Jun 9:107551. PMID: 40499596 -
Spectrochim Acta A Mol Biomol Spectrosc
Spectral signal processing approaches for selective quantification of the recently FDA approved brand-new combination of Vaborbactam and Meropenem; for conformity assessment of bulk and batch release. [Abstract]2020 Apr 5;230:118066. PMID: 31958602 -
mLife
Identification of a phenyl ester covalent inhibitor of caseinolytic protease and analysis of the ClpP1P2 inhibition in mycobacteria. [Abstract]2025 Apr 15;4(2):155-168. PMID: 40313980
Meropenem sodium purchased from MedChemExpress. Usage Cited in: mLife. 2025 Apr 15;4(2):155-168. [Abstract]
Treatment of wild-type BCG with the ClpP-targeting compound GDI-5755 and Ethambutol (ETH) or Meropenem (MPM) significantly reduced the minimum inhibitory concentration (MIC) of each drug.
-
FASEB J
Enhancing the Susceptibility of Methicillin-Resistant Staphylococcus aureus to β-Lactam Antibiotics Through the Use of 4-Methoxysalicyl Aldehyde. [Abstract]2026 Jan 31;40(2):e71438. PMID: 41524623 -
BMC Microbiol
Klebsiella pneumoniae under xylose pressure: the growth adaptation, antimicrobial susceptibility, global proteomics analysis and role of XylA and XylB proteins. [Abstract]2025 Apr 29;25(1):257. PMID: 40301709
Meropenem sodium purchased from MedChemExpress. Usage Cited in: BMC Microbiol. 2025 Apr 29;25(1):257. [Abstract]
To evaluate the influence of various concentrations of xylose on the antimicrobial susceptibility of K. pneumoniae, the MIC values of K. pneumoniaetoward commonly used antibiotics, including Meropenem, Gentamicin, and Ceftriaxone, were determined after xylose exposure at various concentrations.
-
Microorganisms
Antimicrobial Resistance and Genomic Characteristics of Escherichia coli Strains Isolated from the Poultry Industry in Henan Province, China. [Abstract]2024 Mar 13;12(3):575. PMID: 38543626
Meropenem sodium purchased from MedChemExpress. Usage Cited in: Microorganisms. 2024 Mar 13;12(3):575. [Abstract]
Percentages of E. coli strains showing antimicrobial resistance to different antimicrobial agents. AMP, Ampicillin; CAZ, Ceftazidime; IPM, Imipenem; MRP, Meropenem; GEN, Gentamicin; OFX, Ofloxacin; SXT, Trimethoprim–sulfamethoxazole; TET, Tetracycline; TGC, Tigecycline; CL, Colistin; FFC, Florfenicol.
-
Microbiol Spectr
The adaptive growth and mechanisms of Klebsiella pneumoniae under sucrose and glucose exposure. [Abstract]2025 Oct 16:e0160325. PMID: 41099518 -
Microbiol Spectr
Antimicrobial peptide A20L: in vitro and in vivo antibacterial and antibiofilm activity against carbapenem-resistant Klebsiella pneumoniae. [Abstract]2024 Aug 6;12(8):e0397923. PMID: 38980018 -
Open Forum Infect Dis
Trends of β-Lactamase Occurrence Among Escherichia coli and Klebsiella pneumoniae in United States Hospitals During a 5-Year Period and Activity of Antimicrobial Agents Against Isolates Stratified by β-Lactamase Type. [Abstract]2023 Jan 27;10(2):ofad038. PMID: 36776778
Meropenem sodium purchased from MedChemExpress. Usage Cited in: Open Forum Infect Dis. 2023 Jan 27;10(2):ofad038. [Abstract]
Ceftazidime-avibactam, Meropenem, and Imipenem were the most active β-lactam agents tested against 2663 ESBL-producing E. coli and K. pneumoniae isolates that were carbapenem susceptible
-
J Antimicrob Chemother
Harnessing metabolic dependence-driven antibiotic synergy to eradicate tolerant Pseudomonas aeruginosa. [Abstract]2026 Jun 3;81(7):dkag204. PMID: 42267541 -
J Antimicrob Chemother
Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study. [Abstract]2026 Feb 2;81(3):dkag034. PMID: 41648989 -
J Antimicrob Chemother
Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction. [Abstract]2025 Nov 5:dkaf408. PMID: 41206063 -
J Antimicrob Chemother
In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China. [Abstract]2020 Jul 1;75(7):1850-1858. PMID: 32154866
Meropenem sodium purchased from MedChemExpress. Usage Cited in: J Antimicrob Chemother. 2020 Jul 1;75(7):1850-1858. [Abstract]
The cumulative MIC distributions of Cefepime/Taniborbactam, Ceftazidime/Avibactam and comparator Meropenem for 500 tested isolates. The MICs of cefepime and Cefepime/Taniborbactam shown in the figure were tested by the broth microdilution method. The MICs of Meropenem shown in the figure were tested by the agar dilution method. SS, susceptible to all tested β-lactams. SS-P. aeruginosa, meropenem-susceptible P. aeruginosa. Nine IMP producers included three blaIMP-producing P. aeruginosa.
-
J Glob Antimicrob Resist
Exogenous hydrogen sulphide sensitizes carbapenemase-producing Acinetobacter baumannii to gentamicin. [Abstract]2025 Apr 26:S2213-7165(25)00088-8. PMID: 40294863 -
Eur J Clin Microbiol Infect Dis
Evaluation of EUCAST rapid antimicrobial susceptibility testing (RAST) for carbapenemase-producing Klebsiella pneumoniae with focus on KPC variants. [Abstract]2025 Sep 29. PMID: 41023358 -
-
Infect Drug Resist
In vitro Activity of Meropenem-Vaborbactam versus Other Antibiotics Against Carbapenem-Resistant Escherichia coli from Southeastern China. [Abstract]2021 Jun 30;14:2499-2507. PMID: 34234477 -
J Antibiot (Tokyo)
Meropenem, Ceftazidime, and Polymyxin B combination therapy: a novel approach to combat antimicrobial resistance in MDR, XDR and PDR Escherichia coli. [Abstract]2026 Feb 17. PMID: 41703045 -
Infect Genet Evol
Polymyxin B combined with amikacin delays the resistance of Klebsiella pneumoniae to polymyxin B by modulating the expression of NlpE. [Abstract]2025 Sep:133:105780. PMID: 40480594 -
J Microbiol Methods
Comparison of agar-based and checkerboard methods to assess phage-antimicrobial synergy in Pseudomonas aeruginosa. [Abstract]2026 Feb 25:107441. PMID: 41759663 -
Diagn Microbiol Infect Dis
2026 Feb;114(2):117181. PMID: 41205476
純度とドキュメンテーション
参考文献
[1]. L Slaney, et al. In-vitro activity of meropenem against Neisseria gonorrhoeae, Haemophilus influenzae and H. ducreyi from Canada and Kenya. J Antimicrob Chemother. 1989 Sep;24 Suppl A:183-6. [Content Brief]
[2]. George G Zhanel, et al. Comparative review of the carbapenems. Drugs. 2007;67(7):1027-52. [Content Brief]
[3]. Umit Ateskan, et al. Deferoxamine and meropenem combination therapy in experimental acute pancreatitis. Pancreas. 2003 Oct;27(3):247-52. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)